Related Experiment Video
Updated: Feb 9, 2026

Microinjection of mRNA and Morpholino Antisense Oligonucleotides in Zebrafish Embryos.
Published on: May 7, 2009
Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells
Amy E Arnold1, Elise Malek-Adamian2, Phuong U Le3
1Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada.
Abstract:
Glioblastoma stem cells (GSCs) are invasive, treatment-resistant brain cancer cells that express downregulated in renal cell carcinoma (DRR), also called FAM107A, a genetic driver of GSC invasion. We developed antibody-antisense oligonucleotide (AON) conjugates to target and reduce DRR/FAM107A expression. Specifically, we used antibodies against antigens expressed on the GSCs, such as CD44 and EphA2, conjugated to chemically modified AONs against DRR/FAM107A, which were designed as chimeras of DNA and 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA) for increased nuclease stability and mRNA affinity. We demonstrate that these therapeutic conjugates successfully internalize, accumulate, and reduce DRR/FAM107A expression in patient-derived GSCs. This is the first example of an antibody-antisense strategy against cancer stem cells.
Insights
Researchers developed novel antibody-antisense oligonucleotide conjugates to target and reduce FAM107A expression in glioblastoma stem cells, offering a new therapeutic strategy for brain cancer.
Area of Science:
- Oncology
- Molecular Biology
- Neuroscience
Background:
- Glioblastoma stem cells (GSCs) are aggressive, treatment-resistant cells driving brain cancer invasion.
- Downregulated in renal cell carcinoma (DRR), also known as FAM107A, is a key driver of GSC invasion.
Purpose of the Study:
- To develop and evaluate antibody-antisense oligonucleotide (AON) conjugates targeting DRR/FAM107A in GSCs.
- To establish a novel therapeutic strategy for glioblastoma by targeting cancer stem cells.
Main Methods:
- Antibodies against GSC antigens (CD44, EphA2) were conjugated to chemically modified AONs (DNA/2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid chimeras).
- The conjugates were designed for enhanced nuclease stability and mRNA affinity to target DRR/FAM107A.
Main Results:
- The antibody-AON conjugates demonstrated successful internalization and accumulation within patient-derived GSCs.
- Significant reduction in DRR/FAM107A expression was observed in GSCs treated with the conjugates.
Conclusions:
- This study presents the first antibody-antisense approach specifically targeting cancer stem cells.
- The developed conjugates show promise as a novel therapeutic modality for glioblastoma by targeting GSC-specific drivers.
Related Concept Videos
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Induced Pluripotent Stem Cells
Adult Stem Cells
Key Techniques in Microbiology

